BIVI
What one share of BioVie holds
Pharmaceutical Preparations
There is emerging scientific consensus that both inflammation and insulin resistance may play
BioVie’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.05 |
|---|---|
| Cash and investments | $1.19 |
| Book value | $1.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$96.25 | — | −$98.50 | — | $52.50 |
| 2022 | — | −$105.77 | — | −$77.00 | — | $14.69 |
| 2023 | — | −$154.71 | — | −$123.92 | — | $42.11 |
| 2024 | — | −$73.05 | — | −$61.85 | — | $25.05 |
| 2025 | — | −$11.87 | — | −$12.88 | — | $9.93 |
| 2026 | — | −$3.05 | — | −$2.63 | — | $1.36 |